Palatin Technologies Inc

PTN

15.720USD

-0.330-2.06%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Palatin Technologies Inc's Score

Industry at a Glance

Industry Ranking

208 / 392

Overall Ranking

412 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Palatin Technologies Inc Highlights

StrengthsRisks

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The Company's product development activities are focused on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity; ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (DED), and ulcerative colitis, including PL8177, an oral peptide formulation. Its pipeline also includes PL7737 and PL9588. The Company's PL9588 is being developed as a topical treatment for glaucoma.

Overvalued

The company’s latest PE is -2.06, at a high 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

54.333

Target Price

+238.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Palatin Technologies Inc is 7.41, ranking 111 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.41

Change

0



Financials

4.83

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.58

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

No valuation score is currently available for Palatin Technologies Inc. The Biotechnology & Medical Research industry's average is 7.04. Its current P/E ratio is -2.06, which is -83.71% below the recent high of -0.34 and -78.12% above the recent low of -3.67.

Score

Industry at a Glance

Previous score

0.00

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 208/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Palatin Technologies Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 51.50, with a high of 53.00 and a low of 50.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Palatin Technologies Inc is 4.19, ranking 353 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 18.50 and the support level at 13.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.24

Change

-0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Logos Global Management LP

140.00K

--

Point72 Asset Management, L.P.

Star Investors

115.00K

--

Spana (Carl)

6.41K

+9.66%

Wills (Stephen T)

5.30K

-0.13%

Prendergast (John K. A. Ph.D.)

3.87K

+205.37%

Dunton (Alan W)

2.85K

+236.69%

Morris (Arlene M.)

831.00

-0.12%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Palatin Technologies Inc is 1.94, ranking 267 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.46. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Palatin Technologies Inc

PTN

4.78 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment